Andrew M. Evens

17.4k total citations
305 papers, 7.8k citations indexed

About

Andrew M. Evens is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew M. Evens has authored 305 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Pathology and Forensic Medicine, 112 papers in Oncology and 57 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew M. Evens's work include Lymphoma Diagnosis and Treatment (173 papers), Viral-associated cancers and disorders (56 papers) and Chronic Lymphocytic Leukemia Research (41 papers). Andrew M. Evens is often cited by papers focused on Lymphoma Diagnosis and Treatment (173 papers), Viral-associated cancers and disorders (56 papers) and Chronic Lymphocytic Leukemia Research (41 papers). Andrew M. Evens collaborates with scholars based in United States, Canada and France. Andrew M. Evens's co-authors include Leo I. Gordon, Martin S. Tallman, Beverly P. Nelson, Jane N. Winter, Ronald B. Gartenhaus, Borko Jovanovic, Sonali M. Smith, Charles L. Bennett, Jayesh Mehta and June M. McKoy and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Andrew M. Evens

288 papers receiving 7.6k citations

Peers

Countries citing papers authored by Andrew M. Evens

Since Specialization

Citations

This map shows the geographic impact of Andrew M. Evens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew M. Evens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew M. Evens more than expected).

Fields of papers citing papers by Andrew M. Evens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew M. Evens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew M. Evens. The network helps show where Andrew M. Evens may publish in the future.

Co-authorship network of co-authors of Andrew M. Evens

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew M. Evens. A scholar is included among the top collaborators of Andrew M. Evens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew M. Evens. Andrew M. Evens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lymphoma and leukemia occurring during pregnancy 2025 ·Seminars in Perinatology ·Adam Zayac, (unknown), Neil Palmisiano, Andrew M. Evens	1
2	Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model 2024 ·Cell Death and Disease ·Matthew Sullivan, (unknown), Dashnamoorthy Ravi, (unknown), (unknown), Adam K. Ekenseair, Andrew M. Evens, Tania Konry	2
3	Factors associated with health-related quality of life in a cohort of cancer survivors in New Jersey 2023 ·BMC Cancer ·Sharon L. Manne, Katie A. Devine, Shawna V. Hudson, Deborah A. Kashy, Denalee O’Malley, Lisa E. Paddock, Elisa V. Bandera, Adana A. M. Llanos, Angela J. Fong, Neetu Singh, (unknown), Andrew M. Evens	8
4	Sociodemographic and Health Correlates of Multiple Health Behavior Adherence among Cancer Survivors: A Latent Class Analysis 2023 ·Nutrients ·Angela J. Fong, Adana A. M. Llanos, (unknown), Nur Zeinomar, (unknown), Elisa V. Bandera, Katie A. Devine, Shawna V. Hudson, Bo Qin, Denalee O’Malley, Lisa E. Paddock, Antoinette M. Stroup, Andrew M. Evens, Sharon L. Manne	1
5	Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey 2022 ·European Journal of Cancer Care ·Angela J. Fong, Andrew M. Evens, Elisa V. Bandera, Adana A. M. Llanos, Katie A. Devine, Shawna V. Hudson, Bo Qin, Lisa E. Paddock, Antoinette M. Stroup, (unknown), (unknown), Sharon L. Manne	6
6	An Analysis of Transcriptomic Burden Identifies Biological Progression Roadmaps for Hematological Malignancies and Solid Tumors 2022 ·Biomedicines ·Dashnamoorthy Ravi, Afshin Beheshti, Kristine Burgess, Athena Kritharis, Ying Chen, Andrew M. Evens, Biju Parekkadan	1
7	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408 2020 ·Clinical Cancer Research ·Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, P. Cheema, (unknown), Timothy E. O’Brien, Jane N. Winter, Terrence P. Cescon, Julie Chang, Brad S. Kahl	16
8	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium 2020 ·Blood ·Angie Mae Rodday, Susan K. Parsons, (unknown), Ranjana H. Advani, Massimo Federico, Jonathan W. Friedberg, Andrea Gallamini, David Hodgson, Peter Hoskin, Martin Hutchings, Peter Johnson, Kara M. Kelly, Brian K. Link, John Radford, Pier Luigi Zinzani, James R. Cerhan, John Raemaekers, Andrew M. Evens	3
9	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816 2020 ·Leukemia & lymphoma ·Chul S. Ha, Michael LeBlanc, Heiko Schöder, Chelsea C. Pinnix, Nancy L. Bartlett, Andrew M. Evens, Eric D. Hsi, Lisa M. Rimsza, Michael V. Knopp, Jun Zhang, John P. Leonard, Brad S. Kahl, Hongli Li, Sonali M. Smith, Louis S. Constine, Jonathan W. Friedberg	1
10	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma 2018 ·Journal of Clinical Oncology ·Andrew M. Evens, Ranjana H. Advani, Irene Helenowski, Michelle A. Fanale, Sonali M. Smith, Borko Jovanovic, Gregory Bociek, Andreas K. Klein, Jane N. Winter, Leo I. Gordon, Paul A. Hamlin	96
11	Circulating Micrornas (miRNA) As a Novel Liquid Biopsy and Therapeutic Platform in MYC and Non-MYC Diffuse Large B-Cell Lymphoma (DLBCL) 2017 ·Blood ·Afshin Beheshti, Charles Vanderburg, Dashnamoorthy Ravi, J. Tyson McDonald, Amanda L. Christie, (unknown), (unknown), Hong Zhang, David M. Weinstock, Andrew M. Evens	1
12	Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma 2016 ·Cancer Research ·Dashnamoorthy Ravi, Afshin Beheshti, Nasséra Abermil, Frank Passero, (unknown), (unknown), Athena Kritharis, Irawati Kandela, Lynn Hlatky, Michail V. Sitkovsky, Andrew P. Mazar, Ronald B. Gartenhaus, Andrew M. Evens	34
13	Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders 2016 ·Clinical Lymphoma Myeloma & Leukemia ·Aaron S. Rosenberg, Robin Ruthazer, Jessica K. Paulus, David M. Kent, Andrew M. Evens, Andreas K. Klein	13
14	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( PTCL ): final results from the T‐ cell consortium trial 2015 ·British Journal of Haematology ·Ranjana H. Advani, Stephen M. Ansell, Mary Jo Lechowicz, Anne Beaven, Fausto R. Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine M. Foss, Steven M. Horwitz, Barbara Pro, Lauren Pinter‐Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, Julie M. Vose	66
15	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma 2015 ·Clinical Cancer Research ·Andrew M. Evens, Sriram Balasubramanian, Julie M. Vose, Wael A. Harb, Leo I. Gordon, Robert M. Langdon, Julian Sprague, Mint Sirisawad, Chitra Mani, Jeanne Yue, Ying Luan, (unknown), Thorsten Graef, Nancy L. Bartlett	73
16	Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma 2014 ·Clinical Cancer Research ·Sally E. Trabucco, Rachel M. Gerstein, Andrew M. Evens, James E. Bradner, Leonard D. Shultz, Dale L. Greiner, Hong Zhang	116
17	The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models 2014 ·Clinical Cancer Research ·Dashnamoorthy Ravi, Savita Bhalla, Ronald B. Gartenhaus, Jennifer L. Crombie, Irawati Kandela, (unknown), Andrew P. Mazar, Andrew M. Evens	20
18	The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial 2009 ·Clinical Cancer Research ·Andrew M. Evens, William G. Spies, Irene Helenowski, David R. Patton, Stewart Spies, Borko Jovanovic, (unknown), Elizabeth Hamilton, Daina Variakojis, Jun Chen, Louie Naumovski, Steven T. Rosen, Jane N. Winter, Richard Miller, Leo I. Gordon	15
19	PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells 2009 ·Clinical Cancer Research ·Savita Bhalla, Sriram Balasubramanian, Kevin A. David, Mint Sirisawad, Joseph J. Buggy, Lauren Mauro, Sheila Prachand, Richard A. Miller, Leo I. Gordon, Andrew M. Evens	82
20	Initial rate kinetic study of the Pyruvate Translocator in Intact Rat-heart Mitochondria 1993 ·Open Repository and Bibliography (University of Liège) ·Francis Sluse, Claire Duyckaerts, Andrew M. Evens, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact